

# Hepatitis and the Internationally Adopted Child

**Jean Pappas Molleston, MD**

Professor of Clinical Pediatrics  
Pediatric Gastroenterology, Hepatology and Nutrition  
Indiana University School of Medicine  
James Whitcomb Riley Hospital for Children

# Hepatitis A

- Hepatitis A is an acute, not chronic, hepatitis
- Transmitted via fecal-oral route (stool)
- Endemic in many countries, child may already be seropositive on arrival
- Children with chronic liver disease should be immunized against Hepatitis A if not already immune

# Hepatitis B

# Hepatitis B: Demographics

- Endemic areas: SE Asia, Africa, Arctic\*
- High-risk sexual behavior or IV drug use
- Institutionalized children
- Healthcare workers
- Household contacts
- Blood product recipients/dialysis patients
- Internationally adopted children\*

# Hepatitis B: Transmission

- Blood
- Body fluids
- Vertical transmission (mother to child)
- Special issues:
  - Saliva
  - Horizontal spread
  - Insects
  - Daycare

# Prevention of Hepatitis B

- Universal immunization
- Babies born to carrier moms: HBIG within 12 hours of birth, begin immunization immediately
- After exposure: HBIG and immunization if unimmunized
- Immunize family members, avoid sharing razors/ clippers, clean blood spills with bleach and gloves
- Educate regarding safe sex

# Clinical Manifestations of Hepatitis B

- Asymptomatic
- Acute hepatitis
- Fulminant hepatic failure
- Cirrhosis and chronic liver disease
- Hepatocellular carcinoma
  
- Also rash, serum sickness, kidney disease


# Diagnosis of Hepatitis B

- HBsAg: Hepatitis B present
- HB DNA: Quantitates viral load
- HBeAg: Active viral replication
- HBc IgG: Previous exposure to the infection
- IgM: Current infection
- HBsAb: Cleared infection/immune response
- ALT: Reflects necroinflammatory activity
- (Other: Genotype, mutation analysis)


# Outcome of Hepatitis B

- In adults:
  - 90% Recover, becoming HBsAb+
  - 5-10% Chronic infection
  - 1% Fulminant hepatic failure
- In children: Rate of chronic infection is very high when infected in infancy (90%) and decreases with increasing age at infection

# 29 Year Followup of Hepatitis B in 91 Children



# Liver Cancer is Increased in Hepatitis B



# Treatment of Hepatitis B in Children

“All who drink of this remedy recover in a short time. Except those whom it does not help, who all die. It is obvious, therefore, that it only fails in incurable cases”.

Galen (circa 150 AD)

# Treatment of Chronic Hepatitis B in Children (with Elevated ALT)

- Alpha interferon\* injections:
  - Response rate approximately 30%
  - Responders\* HBeAg-/DNA- but usually remain HBsAg+
- Lamivudine orally:
  - Response rate approximately 30%\*
  - Induces mutant virus in 40%

Responder = Less active

\*Virus, not elimination

# Hepatitis C

# Hepatitis C: Transmission

- Blood products, including some IVIG
- IV Drugs
- Healthcare workers
- Sexual (very small risk unless promiscuous)
- \*Vertical transmission (from mother) = 5%
- Unknown (up to 40%)


# Hepatitis C: The Infection

- Incubation 15 - 150 days (mean 50)
- Most patients are asymptomatic although 25% may have malaise, anorexia, jaundice
- Fulminant liver failure rarely if ever occurs
- Antibodies develop by 2 to 6 months

# Diagnosis of Hepatitis C

- Screening: Hepatitis C Ab
- Confirmation: HCV RNA PCR  
(RIBA)
- Research/therapy: Quantitative PCR  
Genotype

# Natural History of Hepatitis C



In chronic hepatitis C

1+1=46%\*

**The New  
Formula for  
Success in  
the Treatment  
of Relapsers**

\*Treatment results of two studies.

Brand names are owned by the relevant companies.  
Registered at The Royal Pharmaceutical Society, London, UK, G.

# Therapy for Hepatitis C in Children

- Interferon/Ribavirin combination therapy:  
Licensed for treatment of hepatitis C in children
- Pegylated Interferon/Ribavirin therapy recently studied: >50% response (HCV-)
- Future directions: Protease inhibitors, other nucleosides, new interferons

# PEDS C Study: Peg IFN +/- Ribavirin for Treatment of Pediatric HCV

- Multicenter RCT of Peg IFN vs Peg/Ribavirin
  - 118 kids nationally; 13 at Riley Hospital
- Compassionate crossover design
- Results at Riley:
  - Overall, 7 of 12 responded
  - IFN monotherapy: 0/6 responded
  - Combo therapy: 7/11 responded
- Results of trial:
  - 53% response rate with combo therapy

# Side-Effects from Interferon/Ribavirin Therapy

- Fevers, flu-like symptoms
- Irritability, behavior issues, depression
- Injection site reaction
- GI symptoms
- Headache
- Weight loss
- Neutropenia/anemia

# Caring for the Child with Hepatitis B or C

- Teach about transmission
- Avoid hepatotoxins (drugs, EtOH, obesity)
- Avoid immunosuppressing if possible
- Keep weight reasonable (avoid NASH – nonalcoholic steatohepatitis)
- Immunize for Hepatitis A and B (unless patient has Hepatitis B virus)
- Monitor PE for evidence of portal hypertension
- Monitor labs for disease activity (ALT)
- Follow alpha-fetoprotein (AFP)/ultrasound for liver cancer

# Hepatitis Summary: When to Worry

- Evidence of portal hypertension (enlarged liver/spleen, low platelets)
- Jaundice
- Marked laboratory evidence of hepatocellular necrosis - ALT's in 100s or more
- Mental status changes

# Viral Hepatitis: Common Questions from Parents

- What will happen to my child in the long run?
- What should I tell the school?
- Are my other children at risk?
- Do herbals work?
- What can I do to help my child's health?

# Good Resources Regarding Viral Hepatitis

- (RHC) Riley Hospital for Children website
- (ALF) American Liver Foundation website
- (CDC) Centers for Disease Control website
- (AAP) American Academy of Pediatrics  
Redbook
- (PKIDS) Parents of Kids with Infectious Diseases  
website